DR Congo's health minister resigned Monday, citing his removal as the head of his country's Ebola response and concerns over a proposed "experiment" with a new, unlicensed vaccine.
"As a result of your decision to place the response to the Ebola outbreak under your direct supervision... I hereby submit my resignation as health minister," Oly Ilunga wrote in a resignation letter to President Felix Tshisekedi.
"As in any war, because that is what this is, there cannot be several centres of decision-making for risk of creating confusion," said the letter.
Ilunga also objected to suggestions "by actors who have demonstrated a clear lack of ethics" to introduce a second vaccine to the country's fight against the highly-infectious haemorrhagic virus disease.
"Strong pressure has been exerted for several months to roll out a new experiment in the DR Congo," he wrote.
Tshisekedi on Saturday replaced Ilunga as the head of the country's response to the latest Ebola epidemic, which has killed more than 1,700 people.
Nearly 170,000 people have been given an Ebola vaccine manufactured by German pharma giant Merck since the outbreak started in Democratic Republic of Congo a year ago.
The World Health Organization (WHO) has been pushing for the introduction of a second vaccine produced by US company Johnson & Johnson, but the health ministry under Ilunga has resisted such a move, citing the risks of introducing a new product in communities where mistrust of Ebola responders is already high.
The Merck vaccine is tested but unlicensed, while the Johnson & Johnson drug is still in the trial investigation stage.
"It would be unrealistic to believe that the new vaccine, proposed by actors who have demonstrated a clear lack of ethics by voluntarily hiding important information from health authorities, could have a decisive impact on the control of the epidemic," said Ilunga, a medical doctor.
He did not refer to anyone by name.
On Saturday, the presidency announced that coordination of the anti-Ebola campaign would now fall under
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
